Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

What Was Tested

The paper reports a study of Exenatide in the context of parkinson's disease, published as a randomized controlled trial.

The researchers aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

Participants were aged 25-80 years with a diagnosis of Parkinson's disease, were at Hoehn and Yahr stage 2·5 or less when on dopaminergic treatment, and were on dopaminergic treatment for at least 4 weeks before enrolment.

All participants and all research team members at study sites were masked to randomisation allocation.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Exenatide, giving a reference point.

More than one site took part, so the participants came from several places.

The researchers did a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial at six research hospitals in the UK.

This study is registered with ISRCTN (14552789), EudraCT (2018-003028-35), and ClinicalTrials.gov (NCT04232969).

What Was Measured

The subject headings attached to it are Disease Progression, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Parkinson Disease and United Kingdom.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in people with parkinson's disease.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Lancet (London, England)), a journal based in England.

More context: the Exenatide compound page, Parkinson's disease research.